IonQ Unveils New Enterprise-Grade Quantum OS and Hybrid Services Suite
2.12.2024 22:05:00 CET | Business Wire | Press release
Full stack development approach drives enterprise-grade capabilities, enabling improved quantum functionality for commercial applicationsIonQ Quantum OS drives an average reduction of over 50 percent in on-system classical overhead, improving time to solution for quantum workloads
IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the launch of its quantum operating system, now called IonQ Quantum OS, and a collection of new capabilities named IonQ Hybrid Services suite. These technologies will greatly advance performance and utility of quantum computing for enterprise customers.
IonQ Quantum OS is a nearly ground-up rewrite of IonQ’s original quantum operating system. Designed and built with a flexible and modular architecture, it is designed to scale and adapt with IonQ’s hybrid quantum computing ecosystem and power IonQ’s current and future flagship quantum computers, including IonQ Forte and IonQ Forte Enterprise.
Designed for improved performance, IonQ Quantum OS dramatically improves time-to-solution, including:
- An average reduction of over 50 percent in on-system classical overhead (compared to identical workloads run on IonQ Forte before the improvements were deployed).
- An 85 percent reduction in cloud and network overhead of workloads submitted through the IonQ Cloud.
- Up to 100x improved accuracy in an expanded error mitigation and compilation suite.
- Enhanced calibration, automation, and control software and firmware to optimize qubit and gate performance and adjust for systemic drifts, resulting in better algorithmic performance.
IonQ Quantum OS also offers enterprise-grade security through improved observability and enhanced interoperability across on-premise hardware and software solutions. These improvements provide customers with new options for securely integrating quantum computing into their stack. IonQ Quantum OS has been running commercial workloads on IonQ Forte since summer 2024 and will soon be operational in controlling IonQ Forte Enterprise as it comes online in IonQ’s Basel, Switzerland data center.
“We designed our Quantum OS not only to address the complex demands of today’s enterprises but to scale seamlessly as their needs evolve,” said Peter Chapman, President and CEO of IonQ. “Our goal is to empower enterprise customers to unlock new possibilities and drive innovation with quantum computing.”
Showcased as an early preview with NVIDIA at SuperCompute 2024, IonQ’s new Hybrid Services suite is designed to enable seamless development and deployment of hybrid workloads that integrate IonQ quantum computers with high-performance classical resources over the cloud. This suite introduces significant advancements to enhance the speed, performance, and usability of quantum workloads, including:
- The Workload Management & Solver Service, a quantum developer toolkit that offers capabilities to efficiently move hybrid workloads to the cloud. This service features a quantum function and hybrid solver designed to help developers simplify the process of manually building circuits and iterative algorithms by packaging them into portable workloads to be executed and enhanced based on their needs.
- A new scheduling feature, Sessions, built on top of IonQ’s Fair Share scheduling engine, is designed to streamline provisioning of QPU time so that iterative and resource-intensive workflows run with minimal wait and interruption. Sessions also provides expanded support for offerings from IonQ’s cloud partners, including Amazon Braket Hybrid Jobs and Azure Quantum Sessions.
- The all-new IonQ SDK allows for seamless, simple, and reliable integration with IonQ Quantum Cloud API and IonQ Hybrid Services.
IonQ Hybrid Services suite is already accelerating the development of real-world, commercial quantum hybrid applications with customers. IonQ recently worked with Oak Ridge National Laboratory (ORNL) to implement a beta version of Hybrid Services to support the development of a NISQ-friendly quantum algorithm, which accelerates time-to-solution for hard optimization problems.
To learn more about IonQ and its latest system news and business developments, visit https://ionq.com.
About IonQ
IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.
IonQ Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words ”will,” “expect,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the expected benefits of IonQ’s quantum operating system and hybrid services suite, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, IonQ’s quantum computing capabilities and plans, the commercial relevance and advantages of applications, and the performance, scalability, accessibility, ease of use, capacity, power, speed, latency, quality, and reliability of IonQ’s quantum computing offerings. IonQ’s quantum computing capabilities and plans, improved efficiency and speed of quantum workloads and algorithms run on IonQ’s quantum computers, and the scalability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ’s ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, forecasts and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers; and events that may impact the security, quality and reliability of IonQ’s technology. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202941767/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom